Tuba TASLAMACIOĞLU DUMAN, Selma ERDOĞAN DÜZCÜ, Meryem DEMİR, Buket Büşra BAŞAR, Ümmügül ÜYETÜRK

An incidentally Diagnosed Hepatocellular Carcinoma That Exhibited Unusual Metastasis

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It can be diagnosed at alate stage due to the lack of early symptom onset and its non-pathognomonic symptoms. Metastaticregions often include the lung, lymph nodes, bones, and adrenal glands. Soft tissue and central nervoussystem (CNS) metastases are extremely rare. The incidence of CNS metastasis ranges from 0.6% to1.7%. Curative treatment is liver transplantation or resection in early stages. In advanced stages, localtherapies include transarterial chemoembolization and radioembolization. Systemic treatments, such assorafenib, regorafenib, ramucirumab, and nivolumab, are applied in the metastatic stage. We aimed topresent with literature the case of HCC that was diagnosed incidentally and had rare metastasis of softtissue and CNS and long-term overall survival.

PDF

___

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sourcesand methods. Int J Cancer 2019;144(8):1941– 53.
2. Chung JW, Jang ES, Kim J, Jeong SH, Kim N, Lee DH, et al. Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. Oncotarget 2017;8(63):106499–510.
3. Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 2016;122(11):1757–65.
4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35–50.
5. Motola-Kuba D, Zamora-Valdés D, Uribe M, Méndez-Sánchez N. Hepatocellular carcinoma. An overview. Ann Hepatol 2006;5(1):16–24.
6. Sartori Balbinot R, Facco Muscope AL, Dal Castel M, Sartori Balbinot S, Angelo Balbinot R, Soldera J. Intraparenchymal Hemorrhage due to Brain Metastasis of Hepatocellular Carcinoma. Case Rep Gastroenterol 2017;11(3):516–25.
7. Rinninella E, Cerrito L, Spinelli I, Cintoni M, Mele MC, Pompili M, et al. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and FuturePerspectives. J Clin Transl Hepatol 2017;5(3):235–48.
8. Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol 2018;6(1):69–78.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378–90.
10.Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25–34.
11.Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, et al. Metronomic capecitabine versus best supportive care as secondline treatment in hepatocellular carcinoma: a retrospective study. Sci Rep 2017;7:42499.
12.Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al.; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56–66.
13.Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011;(3):CD004787.
14.Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, et al.; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734–9.
15.Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One 2017;12(9):e0184597.
16.Kirstein MM, Voigtländer T, Schweitzer N, Hinrichs JB, Marquardt J, Wörns MA, et al. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. United European Gastroenterol J 2018;6(2):238–46.
17.Helal Tel A, Radwan NA, Shaker M. Extrahepatic metastases as initial manifestations of hepatocellular carcinoma: an Egyptian experience. Diagn Pathol 2015;10:82.
18.Yan L, Jakate S, Reddy V, Gattuso P. Metastatic hepatocellular carcinoma diagnosed by fine needle aspiration: A clinical and cytologic study. Diagn Cytopathol 2018;46(6):495–500.
19.Wang S, Wang A, Lin J, Xie Y, Wu L, Huang H, et al. Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget 2017;8(15):25814–29.
20.Ogino A, Hirai T, Serizawa T, Yoshino A. Clinical features of brain metastases from hepatocellular carcinoma using gamma knife surgery. Acta Neurochir (Wien) 2018;160(5):997–1003.
21.Kamimura K, Kobayashi Y, Takahashi Y, Abe H, Kumaki D, Yokoo T, et al. Tumor markers for early diagnosis for brain metastasis of hepatocellular carcinoma: A case series and literature review for effective loco-regional treatment. Cancer Biol Ther 2017;18(2):79–84.
22.Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al.; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16(7):859–70.
23.El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an openlabel, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492–502.